Issue 34

Why Flexibility is Now the Top Priority for CDMOs

Why not sign up for our future email newsletters? Sign up here.

Included in this issue:

LEAD STORY

How Demand for Flexibility is Shaping Facilities of the Future

For decades, successful pharmaceutical manufacturing has been judged on scale. Nowadays, higher precedence is being given to speed, coping with complexity, and customization.

The shift in the global drug development pipeline — from blockbuster molecules to novel targeted therapies — has forced bio/pharma innovators to adapt their strategies to include an increasingly diverse range of therapeutic modalities. As a result, greater demands are being placed on CDMOs to keep pace with their clients’ evolving needs, and leading development and manufacturing partners to re-evaluate how they design, operate, and invest in their facilities.

Read more here.

FEATURED STORIES

From the Editor

Read more here.

Novartis is Expanding its U.S. Manufacturing and R&D Presence

Read more here.

PharmaLogic Strengthens Footing in Radiopharmaceutical Field with Acquisition

Read more here.

AmplifyBio Shuts Down Operations

Read more here.

Accure Therapeutics Granted USD1.6 Million to Advance Parkinson’s Drug Candidate

Read more here.

Amgen’s UPLIZNA Gains FDA Nod for Rare Inflammatory Disease Indication

Read more here.

Granules India Acquires Senn Chemicals to Expand into Peptide Therapeutics

Read more here.